Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease

American Journal of Health-System Pharmacy

Volumn 63, Issue 10, 2006, Pages 915-928

  Chen, Jack J ^a,b,c   Ly, Anh Vuong ^c  

^a U of WI School of Pharmacy   (United States)

^b Temple University School of Medicine   (United States)

^c LOMA LINDA UNIVERSITY   (United States)

Author keywords

Absorption; Aminoindan; Antiparkinson agents; Blood brain barrier; Dosage; Drug comparisons; Drugs, body distribution; Geriatrics; Mechanism of action; Metabolism; Parkinson disease; Permeation; Pharmacokinetics; Rasagiline mesylate; Selegiline; Toxicity

Indexed keywords

ADRENALIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CASPASE 3; CIMETIDINE; CIPROFLOXACIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 4A; ENTACAPONE; EPHEDRINE; FLUVOXAMINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; OMEPRAZOLE; PHENELZINE; PROTEIN BCL 2; RASAGILINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; TRANYLCYPROMINE; TYRAMINE; UNINDEXED DRUG;

ACCIDENTAL INJURY; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; BACKACHE; BALANCE IMPAIRMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CHEESE; CLINICAL TRIAL; CONFUSION; DEPRESSION; DIET RESTRICTION; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TRANSFORMATION; DYSKINESIA; ENZYME INHIBITION; HALLUCINATION; HEADACHE; HUMAN; INFECTION; MENTAL DISEASE; NAUSEA; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYSTEMATIC REVIEW; WEIGHT REDUCTION;

EID: 33646790126     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050395     Document Type: Review

References (106)

1. Schapira AH. Present and future drug treatment for Parkinson's disease. J Neurol Neurosurg Psychiatry. 2005; 76:1472-8.
2. Abeles RH, Tashjian AH Jr. Comparison of the inhibitory effects of propargylamine and pargyline on brain and liver monoamine oxidase activity. Biochem Pharmacol. 1975; 24:307-8.
3. Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet. 1997; 33:91-102.
4. Shin HS. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos. 1997; 25:657-62.
5. Yasar S, Goldberg JP, Goldberg SR. Are metabolites of 1-deprenyl (selegiline) useful or harmful? Indications from preclinical research. J Neural Transm Suppl. 1996; 48:61-73.
6. Abu-Raya S, Tabakman R, Blaugrund E et al. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol. 2002; 434:109-16.
7. Bar-Am O, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett. 2004; 355:169-72.
8. Churchyard A, Mathias CJ, Boonkongchuen P et al. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997; 63:228-34.
9. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002; 59:1937-43.
10. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004; 61:561-6.
11. Rascol O, Brooks DJ, Melamed E et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005; 365:947-54.
12. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO Study. Arch Neurol. 2005; 62:241-8.
13. Youdim MB, Bar Am O, Yogev-Falach M et al. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res. 2005; 79:172-9.
14. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet. 2004; 363:1783-93.
15. Moore DJ, West AB, Dawson VL et al. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci. 2005; 28:57-87.
16. Riederer P, Youdim MB. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with 1-deprenyl. J Neurochem. 1986; 46:1359-65.
17. Green AR, Mitchell BD, Tordoff AF et al. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol. 1977; 60:343-9.
18. Tabakman R, Lecht S, Lazarovici P. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? Bioessays. 2004; 26:80-90.
19. Jenner P. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology. 2004; 63(7, suppl 2):S13-22.
20. Vogel WH, Orfei V, Century B. Activities of enzymes involved in the formation and destruction of biogenic amines in various areas of human brain. J Pharmacol Exp Ther. 1969; 165:196-203.
21. Tallman JF, Saavedra JM, Axelrod J. Biosynthesis and metabolism of endogenous tyramine and its normal presence in sympathetic nerves. J Pharmacol Exp Ther. 1976; 199:216-21.
22. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 1996; 47(suppl 3):S161-70.
23. Riederer P, Youdim MB, Rausch WD et al. On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm. 1978; 43:217-26.
24. Youdim MB, Finberg JP. Monoamine oxidase. In: Lajtha A, ed. Handbook of neurochemistry. Vol. 4: enzymes in the nervous system. 1st ed. New York: Plenum; 1983:293-313.
25. Saura Marti J, Kettler R, Da Prada M et al. Molecular neuroanatomy of MAO-A and MAO-B. J Neural Transm Suppl. 1990; 32:49-53.
26. Paterson IA, Davis BA, Durden DA et al. Inhibition of MAO-B by (-)-deprenyl alters dopamine metabolism in the macaque (Macaca facicularis) brain. Neurochem Res. 1995; 20:1503-10.
27. Ghislandi V, Vercesi D. [Optical resolution and configuration of 1-aminobenzocyclobutene and 1-aminoindane.] Boll Chim Farm. 1976; 115:489-500. In Italian.
28. Binda C, Hubalek F, Li M et al. Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J Med Chem. 2004; 47:1767-74.
29. Kalir A, Sabbagh A, Youdim MB. Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol. 1981; 73:55-64.
30. Maruyama W, Naoi M. Neuroprotection by (-)-deprenyl and related compounds. Mech Ageing Dev. 1999; 111: 189-200.
31. Finberg JP, Tenne M, Youdim MB. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol. 1981; 73:65-74.
32. Finberg JP, Lamensdorf I, Commissiong JW et al. Pharmacology and neuroprotective properties of rasagiline. J Neural Transm Suppl. 1996; 48:95-101.
33. Finberg JP, Youdim MB. Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, type A and type B in the cat. Br J Pharmacol. 1985; 85:541-6.
34. Sterling J, Veinberg A, Lerner D et al. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J Neural Transm Suppl. 1998; 52:301-5.
35. Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan] , a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001; 132:500-6.
36. Thebault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy. 2004; 24:1295-305.
37. Rabey JM, Sagi I, Huberman M et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol. 2000; 23:324-30.
38. Finberg JP, Lamensdorf I, Weinstock M et al. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol. 1999; 80:495-9.
39. Lamensdorf I, Youdim MB, Finberg JP. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem. 1996; 67: 1532-9.
40. Finberg JP, Wang J, Bankiewicz K et al. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J Neural Transm Suppl. 1998; 52:279-85.
41. 11C]deprenyl and positron emission tomography (PET). Mov Disord. 2005; 20(suppl 10):S89. Abstract.
42. Hubalek F, Binda C, Li M et al. Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. J Med Chem. 2004; 47:1760-6.
43. Green AR, Mitchell BD, Tordoff AF et al. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol. 1977; 60:343-9.
44. Youdim MB. Platelet monoamine oxidase B: use and misuse. Experientia. 1988; 44:137-41.
45. Gotz ME, Breithaupt W, Sautter J et al. Chronic TVP-1012 (rasagiline) dose-activity response of monoamine oxidases A and B in the brain of the common marmoset. J Neural Transm Suppl. 1998; 52:271-8.
46. Stern MB, Marek KL, Friedman J et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord. 2004; 19:916-23.
47. Chen JJ, Swope DM. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol. 2005; 45:878-94.
48. Kamada T, Chow T, Hiroi T et al. Metabolism of selegiline hydrochloride, a selective monoamine B-type inhibitor, in human liver microsomes. Drug Metab Pharmacokinet. 2002; 17:199-206.
49. Salonen JS, Nyman L, Boobis AR et al. Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos. 2003; 31:1093-102.
50. Glezer S, Finberg JP. Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens. Eur J Pharmacol. 2003; 472:173-7.
51. Cody JT. Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results. J Occup Environ Med. 2002; 44: 435-50.
52. Finberg JP, Tenne M, Youdim MB. Selective irreversible propargyl derivative inhibitors of monoamine oxidase (MAO) without the cheese effect. In: Youdim MB, Paykel ES, eds. Monoamine oxidase inhibitors: the state of the art. London: Wiley; 1981:31-44.
53. Fowler JS, Volkow ND, Logan J et al. Slow recovery of human brain MAO B after deprenyl (selegiline) withdrawal. Synapse. 1994; 18:86-93.
54. Ravina BM, Pagan SC, Hart RG et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 2003; 60:1234-40.
55. Tatton WG, Chalmers-Redman RM. Modulation of gene expression rather than monoamine oxidase inhibition: (-) -deprenyl-related compounds in controlling neurodegeneration. Neurology. 1996; 47(6, suppl 3):S171-83.
56. Tatton WG, Wadia JS, Ju WY et al. (-) -Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm Suppl. 1996; 48:45-9.
57. Mytilineou C, Radcliffe PM, Olanow CW. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J Neurochem. 1997; 68:434-6.
58. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993; 328:176-83.
59. Maruyama W, Takahashi T, Youdim MB et al. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm. 2002; 109:467-81.
60. Akao Y, Maruyama W, Yi H et al. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett. 2002; 326:105-8.
61. Abu-Raya S, Blaugrund E, Trembovler V et al. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation. J Neurosci Res. 1999; 58:456-63.
62. Goggi J, Theofilopoulos S, Riaz SS et al. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture. Neuroreport. 2000; 11:3937-41.
63. Finberg JP, Takeshima T, Johnston JM et al. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport. 1998; 9:703-7.
64. Bonneh-Barkay D, Ziv N, Finberg JP. Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells. Neuropharmacology. 2005; 48:406-16.
65. Maruyama W, Akao Y, Youdim MB et al. Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J Neural Transm Suppl. 2000; 60:171-86.
66. Kupsch A, Sautter J, Gotz ME et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP1012) with selegiline. J Neural Transm. 2001; 108:985-1009.
67. Blandini F, Armentero MT, Fancellu R et al. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp Neurol. 2004; 187:455-9.
68. Speiser Z, Mayk A, Eliash S et al. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm. 1999; 106:593-606.
69. Speiser Z, Katzir O, Rehavi M et al. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol Biochem Behav. 1998; 60:387-93.
70. Huang W, Chen Y, Shohami E et al. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol. 1999; 366:127-35.
71. Eliash S, Speiser Z, Cohen S. Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. J Neural Transm. 2001; 108:909-23.
72. Eliash S, Shteter N, Eilam R. Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model. J Neural Transm. 2005; 112:991-1003.
73. Heikkila RE, Duvoisin RC, Finberg JP et al. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol. 1985; 116:313-7.
74. Youdim MB, Wadia JS, Tatton WG. Neuroprotective properties of the anti-parkinson drug rasagiline and its optical S-isomer. Neurosci Lett. 1999; 55:S45. Abstract.
75. Maruyama W, Yamamoto T, Kitani K et al. Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech Ageing Dev. 2000; 116:181-91.
76. Naoi M, Maruyama W, Youdim MB et al. Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase. Inflammopharmacology. 2003; 11:175-81.
77. Mandel S, Weinreb O, Amit T et al. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev. 2005; 48:379-87.
78. Maruyama W, Akao Y, Carrillo MC et al. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol. 2002; 24: 675-82.
79. Carrillo MC, Minami C, Kitani K et al. Enhancing effect of rasagiline on superoxide dismutase (SOD) and catalase (CAT) activities in the dopaminergic system in the rat. Life Sci. 2000; 67:577-85.
80. Akao Y, Maruyama W, Shimizu S et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)- aminoindan. J Neurochem. 2002; 82: 913-23.
81. Youdim MB, Amit T, Falach-Yogev M et al. The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activation in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem Pharmacol. 2003; 66: 1635-41.
82. Maruyama W, Akao Y, Youdim MB et al. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3 phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin N-methyl(R)salsolinol. J Neurochem. 2001; 78:727-35.
83. Weinreb O, Bar-Am O, Amit T et al. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 2004; 18:1471-3.
84. Yogev-Falach M, Amit T, Bar-Am O et al. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB J. 2003; 17:2325-7.
85. Maruyama W, Nitta A, Shamoto-Nagai M et al. N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem Int. 2004; 44:393-400.
86. Fahn S, Elton RL, for the UPDRS Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB et al., eds. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Health Care Information; 1987:153-64.
87. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004; 351:2498-508.
88. Hauser RA, Lew MF, Hurtig HI et al. Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson's disease. Mov Disord. 2005; 20(suppl 10):S75. Abstract.
89. Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol. 1996; 40:99-107.
90. Shults CW, Oakes D, Kieburtz K et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002; 59:1541-50.
91. Chen JJ, Berchou RC. Rasagiline, a selective, second-generation, irreversible inhibitor of monoamine oxidase type B, is effective in patients older and younger than 65 years of age with early-to-advanced Parkinson's disease (PD). Pharmacotherapy. 2004; 24:1448. Abstract.
92. Montastruc JL, Chaumerliac C, Desboeuf K et al. Adverse drug reactions to selegiline: a review of the French pharmacovigilance database. Clin Neuropharmacol. 2000; 23:271-5.
93. Gill JR Jr, Masson DT, Bartter FC. Effects of hydroxyamphetamine on the function of the sympathetic nervous system in normotensive subjects. J Pharmacol Exp Ther. 1967; 155:288-95.
94. Martin WR, Sloan JW, Sapira JD et al. Physiologic, subjective and behavioural effects of amphetamine, metamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther. 1971; 12:245-60.
95. Abassi ZA, Binah O, Youdim MB. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol. 2004; 143:371-8.
96. Elmer L, for the Parkinson Study Group. Rasagiline is effective and well tolerated in the treatment of Parkinson's disease (PD) patients with levodopa-related motor fluctuations receiving other adjunctive therapy. Mov Disord. 2005; 20(suppl 10):S138. Abstract.
97. Chen JJ, Berchou RC. Low incidence of cognitive and behavioral adverse events in rasagiline-treated patients with early to advanced Parkinson's disease. Pharmacotherapy. 2005; 25:1466. Abstract.
98. Goetz CG, Schwid SR, Eberly SW et al. Safety of rasagiline in elderly Parkinson's disease (PD) patients. Mov Disord. 2005; 20(suppl 10):S81. Abstract.
99. Da Prada M, Zurcher G, Wuthrich I et al. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl. 1988; 26:31-56.
100. Parkinson Study Group. Tyramine challenge to assess the safety of rasagiline monotherapy in a placebo-controlled multicenter trial for early Parkinson's disease (the TEMPO Study). Neurology. 2001; 56(suppl 3):A345. Abstract.
101. Marcaida JA. Rasagiline does not promote tyramine pressor responses. Mov Disord. 2005; 20(suppl 10):S133. Abstract.
102. Jacob JE, Wagner ML, Sage JI. Safety of selegiline with cold medications. Ann Pharmacother. 2003; 37:438-41.
103. Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline. Lancet. 1991; 337:246. Letter.
104. Richard IH, Kurlan R, Tanner C et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology. 1997; 48:1070-7.
105. Teva. Teva and Lundbeck announce European approval for Azilect (rasagiline) 1 mg for Parkinson's disease. www.levapharm.com/pr/2005/pr_ 514.asp (accessed 2006 Mar 14).
106. Teva. Teva announces that Azilect (rasagiline) is approved for marketing in Israel. www.levapharm.com/pr/2005/pr_500.asp (accessed 2006 Mar 14).